Antivirals Improve Outcomes in Influenza.

Area of Science:

• Virology
• Infectious Diseases
• Public Health

Background:

• Influenza poses a significant global health threat, causing millions of illnesses, hospitalizations, and deaths annually.
• Vulnerable populations, including the elderly and children, are disproportionately affected by influenza.
• Antiviral medications are a key component of influenza management.

Purpose of the Study:

• To evaluate the clinical utility and risk-benefit profile of influenza antiviral medications.
• To inform treatment decisions for different patient populations.
• To assess the efficacy of neuraminidase and endonuclease inhibitors.

Main Methods:

• Review of clinical trial data for neuraminidase inhibitors (oseltamivir, zanamivir, peramivir) and endonuclease inhibitors (baloxavir).
• Analysis of treatment outcomes based on symptom onset time (within 48 hours).
• Stratification of patient groups including hospitalized, severely ill, high-risk, and low-risk outpatients.

Main Results:

• Antiviral treatment, initiated within 48 hours of symptom onset, can shorten influenza illness duration by approximately one day.
• Significant clinical benefits are observed in hospitalized, severely ill, and high-risk patients (elderly, pregnant, immunocompromised).
• For healthy, low-risk outpatients, the clinical benefit of antivirals is modest, with a notable risk of side effects.

Conclusions:

• Influenza antivirals are valuable for specific patient groups, particularly those with severe or high-risk disease.
• The decision to treat low-risk outpatients with influenza antivirals should carefully weigh the modest benefits against potential side effects.
• Early initiation of antiviral therapy is crucial for maximizing treatment efficacy.